ABSTRACT A review of the experimental clinical trials and observational cohort evidence relating serum cholesterol level and its reduction to risks of coronary heart disease (CHD) discloses strong similarities among the quantitative and qualitative relationships found in these studies. Not only are the risk functions similar, but the percent reduction observed is the same as that predicted from the population experience and is proportional to the degree of cholesterol lowering. Furthermore, the risk function is continuous from the highest to the lowest serum cholesterol levels studied. These findings confirm the lipid hypothesis and indicate that lowering serum cholesterol reduces CHD risk. The understanding and control of CHD requires a dual approach: (1) identification and treatment of high-risk individuals, and (2) modification of environmental and behavioral determinants to achieve more favorable distributions of serum cholesterol in populations. Circulation 76, No. 3, 515-522, 1987. A LARGE NUMBER of different types of observational epidemiologic studies, performed in many populations, have confirmed that high total serum cholesterol is a risk factor for coronary heart disease (CHD). These investigations have included (1) of CHD via control of serum cholesterol levels will also be explored.
A LARGE NUMBER of different types of observational epidemiologic studies, performed in many populations, have confirmed that high total serum cholesterol is a risk factor for coronary heart disease (CHD). These investigations have included (1) of CHD via control of serum cholesterol levels will also be explored.
Overview of lipid-lowering trials. In 1981, before the completion of the LRC trial, the results of 11 clinical studies on the effects of lowering lipids were analyzed in an aggregate overview. As described by Mann and Marr,' in an attribution to Peto, to be included in this overview an investigation had to be a unifactor, randomized, lipid-lowering trial in which either a drug or diet was used as intervention. By definition, then, multifactor trials (such as those combining lipid lowering with blood pressure lowering or smoking cessation) were excluded, as were studies in which maneuvers such as physical activity or surgery were used to lower lipids. The characteristics of these studies and the subsequent LRC trial2 are presented in table 1 .
Six of the studies in the overview were diet trials3-8 and five were drug trials.9'3 None of the diet studies selected patients based on hypercholesterolemia, and all were secondary prevention trials. Two of the five drug studies were primary prevention trials, with selection based on hypercholesterolemia. None of the earlier trials selected participants based on LDL cholesterol levels. The LRC trial was a randomized, double-blind, primary prevention study in which the selection criteria included elevation of both total serum cholesterol and LDL cholesterol in middle-aged men free of clinically manifest CHD. The actively treated group received the bile acid sequestrant resin cholestyramine, the control group received placebo, and both adhered to a minimal cholesterol-lowering diet. The cholesterol reduction in subjects randomly assigned to treatment or to no treatment; analyses were based on the experimental design. In addition, internal analyses restricted to the experience of participants within the cholestyraminetreated group of the LRC trial (and therefore of a nonexperimental, observational nature), disclosed a dose-relationship between the amount of cholesterol reduction achieved and the reduction in relative risk. 14 In figure 2 , the points representing the relative risk of CHD within the cholestyramine group are arrayed in a stepwise fashion in relation to cholesterol reduction. The point representing the overall result of the LRC trial in its experimental mode (comparing cholestyramine to placebo) falls close to that predicted from the experience within the cholestyramine group.
In contrast to the overview of lipid-lowering trials, in which the level and range of total serum cholesterol reduction achieved was quite low, analysis of the experience of men within the actively treated cholestyramine group of the LRC trial permits comparison over a wide range of total cholesterol reduction achieved by individuals. A sizable proportion of individuals in this group had a reduction in serum cholesterol greater than or equal to 25% with a predicted reduction in CHD risk of 50% and an observed reduction in excess of this amount. These analyses cannot unequivocally be attributed to the treatment regimen per se, since the observations were not derived from an experimental randomly assigned to placebo demonstrated no such association between amount of drug (placebo) taken and CHD risk. The markedly reduced risk observed (and predicted) with serum cholesterol reductions of 25% or greater in the LRC study indicate the potential for major clinical impact, but this has not been as apparent in the overall efficacy noted in any of the trials reported to date (with a maximum average cholesterol reduction of 16% reported). When the diet and drug trials are considered separately, little relationship between either absolute or percent reduction in serum total cholesterol and baseline cholesterol level is evident ( figure 3 ). It should be noted that regression to the mean would be expected to produce an association between the baseline level and change. 15 This discussion of association is not intended to imply any causal relationship between these measures. It indicates, rather, that the overall cholesterol reduction achieved in these studies was minimal, despite the range of more than 156 mg/dl of serum cholesterol levels at baseline across trials (many with participants whose serum cholesterol levels were considered clinically normal at the time of investigations).
The demonstration of reduction in CHD risk under these circumstances leads to optimism regarding the potential for enhanced efficacy with the greater serum cholesterol lowering that should be achievable with the agents now available. An exponentially increasing risk of CHD with increasing baseline levels of total serum cholesterol has been reported within each study. There has been debate in the past as to whether or not the summarization of these observations by a single, monotonically increasing function best represents the relationship. Some observers have argued, for instance, that a threshold value exists below which there is no association of serum cholesterol with CHD, or that there may be a curvilinear relationship with an increase in some forms of cardiovascular disease (such as cerebrovascular disease) at the lowest levels of total serum cholesterol. The coefficients of all studies were covariance adjusted for systolic blood pressure and cigarette smoking. Those for the "seven countries" populations were also adjusted for age and body mass index. The coefficient for the LRC trial was based on a proportional-hazards rather than a logistic model and was adjusted for age, high-density lipoprotein cholesterol, triglyceride, and exercise test outcome at baseline, as well as smoking and systolic blood pressure.
Stratified analyses of most earlier studies have been inconclusive, since partitioning the cohort by quantiles of cholesterol levels produced strata too small to yield stable estimates of risk. In contrast, the recently reported 5 year mortality follow-up of the more than 300,000 white male subjects in the Multiple Risk Factor Intervention Trial (MRFIT) disclosed a step function with no evidence of a threshold value on stratified quintile analysis. 17 In addition to continuity of the relationship, of particular note is the quantitative similarity of the logistic regression coefficients among most of the earlier reported studies and the similarity of the recently reported logistic regression coefficient of the mortality follow-up of the MRFIT and Framingham subjects and the LRC trial placebo group. These findings not only indicate an increasing incidence of fatal and nonfatal CHD with increasing serum cholesterol levels in each of the studies, but show that the rate of increase is similar across these investigations. These slopes, each relating differences in CHD risk to differences in initial total cholesterol levels, were controlled for the other standard risk factors. The epidemiologic observational data of the Framingham study were used to estimate the expected event rate in the placebo group of the LRC trial during its planning and design. The partial regression coefficient estimating the increase in CHD risk with increasing cholesterol level, controlling for the other major risk factors, was similar in the two studies (.0068 for Framingham and .0079 for the LRC trial), as was the average level of CHD.
Marked extrapolation of the LRC trial experience to extremely lower values, therefore, is notjustified; however, the overall similarities of the risk functions for the hypercholesterolemic men and the population sample suggest that some extrapolation is meaningful. The rationale and justification for this extrapolation has been increased by the availability of the mortality follow-up experience of the MRFIT subjects. The when clinical end points are assessed. Extrapolations, therefore, must be made from clinical trials including patients with higher levels of total serum cholesterol. Under these circumstances, safety considerations become particularly relevant; since the absolute risk decreases with decreasing levels of total serum cholesterol, any hazard induced by the intervention technique assumes increasing importance.
All-cause mortality. Although the incidence of definite and suspect CHD death was reduced by 24% and 30%, respectively, in the cholestyramine-treated group in the LRC trial, all-cause mortality was reduced by only 7% and was not significantly different from zero. Inspection of the causes of mortality by major categories (in addition to the cardiovascular deaths), such as the aggregate of malignancies, disclosed no differences that were noteworthy, with the exception of 11 deaths from accidents and violence in the cholestyraminetreated group compared with four in the placebo group. Since no cause or connection could be established between cholestyramine treatment and violent or accidental death, the LRC investigators concluded that this difference was a chance occurrence. Notice was made, however, of the fact that several other primary prevention trials reported higher noncardiovascular mortality rates in their active treatment groups. In contrast to the excess in violent deaths observed in the actively treated group of the LRC trial, in other studies the excess resulted from a variety of medical causes. In drug studies of this type, explanations must include the possibility of iatrogenesis directly related to the specific pharmacologic agents used in reducing serum lipids. Several prior studies disclosed evidence of possible toxic effects from drugs such as clofibrate, " high-dose estrogen in men,18 and dextrothyroxine.'9 Although there is no significant evidence of an excess mortality as a result of medical conditions within the cholestyramine-treated LRC group, this cohort will continue to be observed for long-term sequelae.
Observational epidemiologic studies have yielded inconsistent findings regarding the association between serum cholesterol levels and all-cause mortality, which is quite different from the consistent association seen between total serum cholesterol and CHD events. In some population studies (for example, the OS1020 and Chicago Gas Co. and Chicago Western Electric Co. studies21), the relationship has been positive -a stepwise increase in mortality from all causes with increasing cholesterol levels. In other populations, the relationship has been curvilinear, with increases in mortality at both the high and low extremes of cholesterol levels; this has been observed in the Conclusions. This review of the experimental clinical trials and observational cohort evidence relating level and reduction of serum cholesterol to CHD risk has disclosed strong similarities in the relationships, both quantitative and qualitative, observed among studies. The risk functions are similar, the percent reduction observed in clinical trials is that predicted from the population experience and is proportionate to the amount of cholesterol lowering achieved, and the risk function is continuous from highest to lowest serum cholesterol levels studied. The similarities of risk functions across the wide range of serum cholesterol levels are particularly noteworthy given the marked differences in times and places of the studies (with CHD mortality markedly differing by place and time), and with differences in the personal characteristics of individuals studied. This suggests that, despite a wide variety of factors influencing the level of CHD in the population, the relationship of coronary disease risk to serum cholesterol is similar at "all" levels. These findings, added to the large body of extant evidence from other sources, not only confirm the lipid hypothesis but indicate that lowering serum cholesterol lowers CHD risk. The other major risk factors, in addition to cholesterol, appear to have similar effects in the general population and in high-risk individuals, although there is the potential for an interactive effect in high-risk individuals.
The specific treatment regimen for high-risk persons requires a tailored program with assessment ofrisks and benefits on an individual basis. The population approach requires consideration of cholesterol as a graded characteristic distributed in populations with increasing CHD risk at increasing levels. Identifying appropriate target populations and modalities for the safe, effective prevention or treatment of elevated plasma LDL cholesterol in individuals and populations as a whole requires a review of existing evidence in addition to the observational cohort and clinical trial results reviewed here, as well as further research.29
